1. This study was designed to test the hypothesis that acid-base status affects the response to a loop diuretic in human subjects. The renal responses to bumetanide ( 1 mg intravenously) were studied in eight normal subjects consuming a constant diet supplemented for 3 days on three separate occasions with equivalent quantities of NaCI, NaHCO3 (metabolic alkalosis) or NH4CI (metabolic acidosis).
INTRODUCTION
Therapy with loop diuretics is frequently accompanied by a chloride-depletion metabolic alkalosis [l, 21 . Some studies in experimental animals have concluded that the acid-base status does not alter the response to a thiazide [3] or ethacrynic acid [4] . However, Hook and Williamson [5] demonstrated that acute metabolic alkalosis in dogs diminished the natriuretic and chloruretic response to frusemide. The present studies were undertaken to test the hypothesis that the acid-base status, uncomplicated by major changes in extracellular fluid volume produced by regular diuretic therapy, determines the responsiveness to loop diuretics in man. We compared the renal response to a single dose of bumetanide given to normal human subjects during substitution of equivalent quantities of NaHCO3 or NH4Cl for NaCl in the diet. Bumetanide was selected because, unlike frusemide, it has no effect on renal carbonic anhydrase (as reflected in H C 0 3 excretion) at normal therapeutic doses [l] and does not interact with the thiazide-sensitive electroneutral NaCl transport process in the early distal tubule [6] .
METHODS
Eight normal subjects were admitted to the Clinical Research Center after giving informed consent as approved by the Institutional Review Board. They were placed on a regulated diet containing 20 mmol of sodium and chloride, 70mmol of potassium and 60 mmol of acid-equivalent daily for 10 days. This was supplemented for the first 3 days with tablets of NaCl administered orally three times daily to give a total of 103 mmol/day. Thereafter, the subjects were randomized to receive NH4Cl tablets (112 mmol/ day) or NaHCO3 tablets (108 mmol/day). Those receiving NH4Cl initially were changed to NaHC03 after 3 days, and vice versa. Thus, all subjects received, for 3 days, diets containing: (i) NaCI, 123mmol Na+ and 123mmol C1-; (ii) NHKl, 112 mmol NH:, 20 mmol Na+, and 132 mmol C1-; and (iii) NaHC03, 128mmol Na+, 108mmol HCOT, and 20 mmol Cl-. Sitting blood pressure (BP) was recorded daily before breakfast; mean BP was calculated from the diastolic BP (Korotkoff sound IV) and one-third of pulse pressure. A 24 h urine collection was made on the day before each study day.
After completing 3 days of each diet (on days 4, 7 and lo), the renal response to bumetanide was assessed. At 08.00 hours, after a light breakfast, the subject was weighed, an intravenous infusion line was placed in one arm, and a blood sampling port in the other. An intravenous loading dose of paraaminohippurate (PAH), 8.6 mg/kg, was followed by a constant infusion containing 0.20 mg.min-'.kg-'. The subjects remained sitting throughout the study except during voiding. Spontaneous voiding and a high basal urine flow were facilitated with an oral water load of 7ml/kg given at the beginning of the study. After 1 h for equilibration, a basal 2 h urine collection was made for measurement of urine pH up^), bicarbonate (HCOT), electrolytes, PAH and creatinine (Cr). A midpoint basal blood specimen was obtained for similar determinations and for haematocrit, plasma renin activity (PRA) and plasma aldosterone concentration. An arterialized venous sample was collected [l] for blood gas measurement. At the conclusion of the basal urine collection, bumetanide (Bumex; Roche Pharmaceuticals, Nutley, NJ), 1 mg, was given intravenously over 2 min. Subsequently, five 30 min urine collections, with midpoint blood samples for PAH and Cr, were obtained. A further blood sample for PRA, plasma aldosterone and haematocrit was taken during the final clearance period. Heart rate and BP, measured with a standard mercury sphygmomanometer, were recorded at the beginning and end of each urine collection. The test response period lasted 2.5 h since we had found previously that this encompassed >95% of the natriuretic response to intravenous bumetanide in normal subjects [7] . Thereafter, 1 litre of fluid was infused intravenously. The composition of the fluid was designed to replace major fluid and electrolyte losses and restore acid-base status before starting the subsequent 3 day diet period. Therefore, after the bumetanide diuresis and the NaCl diet, the infusion was composed of Na+, 154mmol/l; K+, 20mmol/l; C1-, 174 mmol/l. After the corresponding period on the NaHC03 diet it was: NH:, 154mmol/l, C1-, 174 mmol/l; K+, 20 mmol/l, whereas after the NH4CI diet it was: Na+, 154mmol/l; HCOT, 174 mmol/l; K+, 20 mmol/l.
Plasma volume was estimated during the basal period from the initial volume of distribution of Evans Blue dye (Harvey Laboratories, Inc., Philadelphia, PA, U.S.A.). Each subject received approximately 10mg of dye; the precise quantity administered was determined by weighing the syringe before and after intravenous injection. Plasma samples were drawn before and 10, 20 and 30 min after the injection. They were compared with standard curves made up in each subject's own plasma drawn before dye administration. The Evans Blue dye concentration was estimated after the extraction of plasma lipids [S] . The initial plasma concentration was determined by extrapolation of the plasma concentration to zero time.
Creatinine was measured with a creatinine analyser (Beckman, Fullerton, CA, U.S.A.) and PAH colorimetrically [9] . Na+ and K+ concentrations in plasma and urine were measured by a flame photometer (IL 443; Fisher Scientific, Orlando, FL, U.S.A.) and CI-potentiometrically (920M; Corning Inc., Medfield, MA, U.S.A.). Blood pH and partial pressure of COZ (PCO~) were analysed in a blood gas analyser (Instrumentation Laboratories, Inc., Lexington, MA, U.S.A.) and plasma bicarbonate concentration (PHco~) was calculated from these. Urine for pH and bicarbonate analysis was placed on ice and analysed without delay. up^ was measured with a pH electrode (EA 940; Orion Instruments Inc., Boston, MA, U.S.A.) and UHCO~ from COz evolved by lactic acid (Total COz Analyser; Corning Inc, Medfield, MA, U.S.A.). The haematocrit was taken as the mean of two determinations in a microhaematocrit centrifuge (Clay-Adams, Inc., Parsippany, NJ, U.S.A.). PRA was determined after generation of angiotensin I for 90 min at 3TC, using a specific RIA (Travenol-Genetech Diagnostics, Cambridge, MA, U.S.A.), and plasma aldosterone by RIA (Diagnostic Products Corp., Los Angeles, CA, U.S.A.). Urine for catecholamine was acidified as soon as it was passed and an aliquot stored at -70°C for subsequent analysis of noradrenaline, adrenaline and dopamine [lo] . Bumetanide concentration in urine was determined after extraction and purification using HPLC and fluorescence detection as previously described [ 111.
Statistical analysis was performed with an analysis of variance. The mean of the five post-diuretic clearance periods was taken to compare bumetanide responses to baseline. Data are presented as means f S.E.M.s and statistical significance assumed at P < 0.05.
RESULTS
Eight subjects (aged 21-65 years) entered and completed the study. No subject encountered any adverse effects from the protocol. Table 1 presents serum values obtained during the basal period on the experimental days and data for Na+ and CIexcretion over the 24 h before the studies. The 
-
serum and plasma values demonstrate a consistent but quite mild degree of metabolic acidosis and metabolic alkalosis in the subjects while they were receiving the diets supplemented with NHKl and NaHC03. Sodium excretion was strictly comparable during NaCl and NaHC03 and was not significantly different from the level of intake. During dietary supplementation with NH4C1, Na+ excretion was lower than during diets containing sodium supplements but was significantly (P < 0.001) above the level of intake. Chloride excretion was comparable during the NaCl and NH4CI diets and was not significantly different from the level of intake. During NaHC03, C1-excretion was greatly reduced to levels equivalent to intake. Therefore, at the time of diuretic testing, there were only very modest changes with NaHC03 or NH4Cl in systemic parameters of acid-base status, whereas the urine reflected these differences quite clearly. The subjects appeared to be in neutral balance for Na+ and C1-except for a negative balance for Na+ during supplementation with NH4Cl. Basal plasma volume was not significantly different during each diet period [2775+137 (NaCl) versus 2557 f 87 ml (NaHC03) versus 2703 & 117 ml (NH4Cl); n = 8, not significant]. Figure 1 shows the levels of PRA and plasma aldosterone. In the basal state, the PRA tended to be higher during NH4Cl and NaHCOs, but the differences from NaCl were not significant. Bumetanide increased PRA similarly during each diet period. Basal levels of plasma aldosterone were elevated significantly during NH4Cl compared with NaCI, and remained so after bumetanide. Plasma -T I aldosterone was comparable during NaCl and NaHC03, both before and after bumetanide.
As shown in Table 2 , in the basal state, renal dopamine excretion was reduced during NaHC03. Bumetanide led to a consistent increase in noradrenaline excretion that was similar during each acidbase condition without significant effects on the excretion of adrenaline or dopamine.
Mean BP and clearance of Cr and PAH (Cc, and CPAH) were similar in the basal state and after bumetanide on all three study diets (Table 3) . Table 4 shows the urine flow and renal electrolyte excretion rates in the basal state during water loading and the changes with bumetanide. The rates of Na+ excretion were higher than during the prior 24 h collection (78-146 compared with 40-86 pmol/ min), probably reflecting the effects of circadian variation and water loading. The basal urine flow rates were similar for the three acid-base conditions. Compared with the NaCl diet, the basal UNaV and fractional excretion (FE) of Na were decreased and the UKV and FEK increased during NH4C1, whereas the basal UCIV and FECI were decreased during NaHC03. The basal rate of HCOT excretion was elevated during NaHCO3.
Compared with NaCl, there were significant reductions in bumetanide-induced diuresis ( -40.3%, P < 0.01), natriuresis (UNaV, -21.4%; FEN^, -20.5%, P < 0.01) and chloruresis (UCIV, -24.6%; FEcI, -18.3%, P<0.025) during NaHC03. In contrast, NH4Cl did not change the diuretic, natriuretic or chloruretic response to bumetanide. Bumetanide did not change HC03 excretion. It raised K+ excretion significantly more during NH4Cl than NaCl. The rate of renal bumetanide excretion (Fig. 2) was significantly elevated during NaHC03 compared with NaCl but was unchanged during NH4CI. Thus, during NaHC03, natriuresis diminished despite increased renal diuretic excretion.
Linear regression analysis was undertaken with basal U N~V , UCIV and U H C O~V as independent variables and renal responsiveness as the dependent variable. A significant positive correlation was obtained between renal responsiveness to bumetanide and basal UCIV (r = +0.48, P = 0.016), and a negative correlation with basal UHCOJ (r = -0.46, P = 0.025). Since multiple regression analysis using basal UCIV and U H C O~V did not improve the overall correlation coefficient, these were probably not independent variables under the conditions of our study. No significant correlation was found between renal responsiveness and basal UN,V (r = -0.10; not significant).
DISCUSSION
The present study shows that dietary substitution of NaHC03 for NaCl impairs the natriuretic and chloruretic response to a loop diuretic, whereas sub- stitution with NH4Cl does not affect it. A study in dogs concluded that there was no significant effect of induced alkalosis or acidosis on the response to ethacrynic acid [4] . However, this study shows a 20-30% reduction in natriuresis and chloruresis after NaHCO3 infusion. Hook and Williamson [5] found that alkalosis in the dog reduced the natriuretic and chloruretic response to frusemide by 22% and 31% respectively. Another study in dogs [12] showed no effect of moderate chronic NH4Cl-induced acidosis on the response to ethacrynic acid, as in the present study with bumetanide, although very severe acidosis (blood pH 7.08) increased the natriuretic response. Likewise, in the rabbit, meta- bolic acidosis does not alter the response to frusemide [13] . We considered five mechanisms that may account for the impaired response during NaHC03.
First, NaHC03 could have inhibited natriuresis if it had reduced the delivery of the diuretic to its site of action. The response to bumetanide depends on its proximal secretion and luminal delivery to the thick ascending limb of the loop of Henle since urinary, but not plasma, levels determine the natriuresis [ 141. Bumetanide excretion increased during NaHC03. Prolonged frusemide therapy also increased the rate of frusemide excretion [9] . Alkalosis enhances ethacrynic acid excretion in the dog [15] and enhances PAH uptake in vitro into rabbit kidney slices [16] . Loop diuretics and P A H are secreted into tubular fluid by a similar transport process. Therefore, the mild metabolic alkalosis accompanying NaHC03 administration may have enhanced proximal secretion of bumetanide. Regardless, NaHC03 impairs the response to bumetanide despite increased delivery of diuretic to the urine.
A second mechanism that could impair natriuresis during NaHCO3 is a decreased filtered load of Na+. However, Ccr was unchanged during the mild degree of alkalosis in the present protocol, and therefore glomerular filtration rate and the filtered load of Na+ are unlikely to have been significantly curtailed.
A third mechanism that could impair the natriuretic response to a loop diuretic is enhanced proximal tubular fluid reabsorption with consequent decreased delivery of solute and chloride to the site of diuretic action. Proximal fluid reabsorption is very sensitive to extracellular fluid volume depletion. However, the plasma volume, measured by dye dilution, was unchanged during NaHC03, as was the basal noradrenaline excretion, which is taken as an index of sympathetic nervous system activity, although there was a tendency to a reduced plasma volume of about 5%. Prolonged metabolic alkalosis in rats or rabbits enhances proximal tubular fluid reabsorption and leads to proximal tubule hypertrophy [15, 171. However, in rats studied during acute, mild metabolic alkalosis, there is maintained fluid and chloride reabsorption by the proximal tubules of superficial [ 181 or juxtamedullary nephrons [19] . An acute, mild metabolic alkalosis does not impair proximal H C O l reabsorption [19] . Therefore, tubular fluid delivery from the proximal tubule during NaHC03 should be relatively well preserved, unless there was a physiologically important fall in plasma volume leading to enhanced proximal fluid reabsorption. However, during NaHC03, the tubular fluid delivered to the loop of Henle probably has a reduced [Cl-1. The Na+-K+-2Cl-luminal co-transporter in the thick ascending limb has affinities for Na+, K+ and C1-of 7, 1.3 and 67mM respectively [20, 211. The tubular fluid "a+] and
[K+] are likely to be well above their Km values and therefore should not be limiting for reabsorption via this transporter. In contrast, the [Cl-] of tubular fluid might be sufficiently reduced during NaHC03 to diminish reabsorptive flux through the Na+-K+-2C1-cotransporter and thereby to reduce the inhibition by bumetanide. This possibility is suggested by the positive correlation observed in these studies between renal responsiveness to bumetanide and basal excretion of C1-but not Na+. Because the degree of alkalaemia induced by NaHC03 in these protocols was quite modest, whereas its effects on the urine composition were quite pronounced, it is more likely that changes in intratubular urine composition, rather than systemic alkalosis, were predominant in the reduced renal response to the diuretic.
A fourth mechanism that might account for decreased responsiveness to bumetanide during NaHC03 is a change in the expression or composition of the Na+-K+-2Cl-co-transporter. Recently, Ecelbarger et al. [22] reported that, during chronic frusemide administration in the rat, there was an apparent increase in the molecular mass of the bumetanide-sensitive co-transporter in the thick ascending limb. They suggested that this was due to enhanced glycosylation and one may speculate that it was a response to alkalosis and might alter the transporter's activity. Clearly, any such change in the co-transporter with NaHC03 could alter bumetanide binding and responsiveness.
A fifth possible explanation for a decreased response to a loop diuretic during alkalosis is enhanced reabsorption in downstream nephron segments. Studies in rats during short-term metabolic alkalosis have shown that there is enhanced fractional reabsorption of CI-by the superficial distal tubule and a sharply enhanced reabsorption of CIin hypertrophied collecting ducts [23, 241 that could mask the effects of ongoing inhibition of loop reabsorption by bumetanide during alkalosis.
Reabsorption of Na+ in the distal nephron and collecting ducts is enhanced by aldosterone. However, plasma aldosterone levels were unchanged during alkalosis and therefore cannot account for the blunted natriuretic response to bumetanide. Of interest was the observation that metabolic acidosis increased plasma aldosterone concentration without a significant increase in PRA or serum potassium concentration. This confirms previous findings in dogs [25] which have been related to increased adrenocorticotropic hormone secretion [26] . The increase in plasma aldosterone concentration during acidosis may have contributed to an increased excretion of K+.
Alkalosis decreased the basal rate of dopamine excretion. Although dopamine is natriuretic, this finding is unlikely to explain the decreased response to the bumetanide, since the diuretic itself did not increase dopamine excretion during any acid-base condition. Since there were no significant differences between the protocols in PAH or Cr clear-ance, it is likely that catecholamine excretion reflects plasma catecholamine levels rather than changes in renal delivery or filtration. Similar rates of renal excretion of noradrenaline or adrenaline between different acid-base conditions are interpreted to mean that there were not major differences in sympathetic nervous system activity. The increase in noradrenaline excretion with bumetanide confirms a previous finding that it increases plasma noradrenaline concentration [lo] . The observation that noradrenaline excretion increased similarly between protocols suggests a similar degree of sympathetic nervous system stimulation, probably in response to the reduction in blood volume.
In summary, metabolic alkalosis attenuates the natriuretic response to a single dose of bumetanide despite increasing bumetanide excretion. Neither a change in the filtered loads of Na+ or C1-nor an altered renin-aldosterone axis nor a major change in the sympathetic nervous system, renal haemodynamics, plasma volume or BP can explain this diminished response.
A single dose of loop diuretic raises the plasma HCOT concentration by 2-3 mmolfl due predominantly to contraction of the extracellular H C 0 3 space [ l , 21.
The present results raise the possibility that metabolic alkalosis may be one of several factors that diminish responsiveness to loop diuretics during prolonged therapy and may therefore be a factor contributing to the diuretic braking phenomenon [27] and diuretic resistance. However, diureticinduced alkalosis results largely from CI-depletion, whereas in this study it resulted from HCOT administration. Therefore, further studies will be required to determine the contribution of alkalosis or impaired tubular C1-delivery to the impaired diuretic responses in clinical states of resistance.
